SCHEMBL23218206

SCHEMBL23218206

COC(=O)Cc1cccc(OCc2coc3ccc(-c4cccc(CN)c4)cc23)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 3/20 0.50
FFAR1 O14842 1/20 0.45
PSMB5 P28074 4/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
F11 P03951 1/20 0.39
KLKB1 P03952 1/20 0.39
F7 P08709 1/20 0.39
TPSB2 P20231 1/20 0.39
ANO1 Q5XXA6 2/20 0.39
PTGER4 P35408 2/20 0.37
ESR1 P03372 1/20 0.37
THRA P10827 1/20 0.37
THRB P10828 1/20 0.37
VDR P11473 1/20 0.37
RXRA P19793 1/20 0.37
PPARG P37231 1/20 0.37
PPARD Q03181 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852740 1.00 CFD (0.50) CFDFFAR1PSMB5MAOAMAOB
SCHEMBL23218518 0.89 CFD (0.61) CFDFFAR1PSMB5PLGPLAU
SCHEMBL29591826 0.89 CFD (0.61) CFDFFAR1PSMB5PLGPLAU
SCHEMBL23218756 0.84 CFD (0.51) CFDFFAR1PLGPLAUF11
SCHEMBL23218494 0.83 MAOB (0.52) FFAR1PSMB5MAOAMAOBMTNR1A
SCHEMBL29852668 0.83 CFD (0.45) CFDFFAR1MAOAMAOBPLG
SCHEMBL23218403 0.83 CFD (0.45) CFDFFAR1MAOAMAOBPLG
SCHEMBL28736109 0.82 CFD (0.44) CFDFFAR1PSMB5PLGPLAU
SCHEMBL29853127 0.82 CFD (0.44) CFDFFAR1PSMB5PLGPLAU
SCHEMBL23218306 0.79 CFD (0.46) CFDFFAR1MAOAMAOBPLG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885FFAR1 3516/4885PSMB5 2941/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885FFAR1 3234/4885PSMB5 1475/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.